文献速递免疫规划传染病防控与疫情报告

SARS-CoV-2感染后6个月内的免疫原性因既往COVID-19疫苗方案和是否接种加强针而显著不同

Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.
PubMed 文献 · Vaccine · 2024-06-08

一项前瞻性队列研究在Omicron变异株流行期间纳入871名COVID-19高风险成人,随访感染后0、14、90和180天的抗棘突RBD水平。264人(30.3%)感染COVID-19,感染者基线抗棘突RBD几何均值显著低于未感染者(326 vs. 989;P < 0.001)。感染者抗棘突RBD水平在感染后14天显著升高最多,在第90天和第180天显著下降;感染后91-180天接种加强针可在180天内诱导高水平抗棘突RBD。

要点

  • 感染者基线抗棘突RBD几何均值显著低于未感染者(326 vs. 989;P < 0.001)。
  • 感染者抗棘突RBD水平在感染后14天显著升高最多,第90天和第180天显著下降。
  • 感染后91-180天接种加强针可在180天内诱导高水平抗棘突RBD。

核心结论

  • SARS-CoV-2感染诱导高水平但短暂的免疫,维持免疫需在感染后90天起接种加强针。

研究设计与样本

  • 前瞻性队列研究,在Omicron变异株流行期间纳入871名COVID-19高风险成人,随访感染后0、14、90和180天的抗棘突RBD水平。

主要发现

  • 871人中264人(30.3%)感染COVID-19。
  • 感染者基线抗棘突RBD几何均值显著低于未感染者(326 vs. 989;P < 0.001)。
  • 感染者抗棘突RBD水平在感染后14天显著升高最多,第90天和第180天显著下降。
  • 感染后91-180天接种加强针可在180天内诱导高水平抗棘突RBD。

临床怎么用

  • 作者认为,SARS-CoV-2感染诱导高水平但短暂的免疫,维持免疫需在感染后90天起接种加强针。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data on immunogenicity induced by SARS-CoV-2 infection and its sustainability are essential to inform COVID-19 vaccine schedule. A prospective cohort study was conducted among adults at-risk for COVID-19 during the Omicron variant-dominant epidemic. All were followed up for anti-spike RBD levels on days 0, 14, 90 and 180 after enrollment. Of the 871 individuals included, 264 (30.3 %) had COVID-19. Those with COVID-19 had significantly lower baseline geometric mean level of anti-spike RBD than those without COVID-19 (326 vs. 989; P < 0.001). Among the COVID-19 patients, anti-spike RBD level significantly increased the most at 14 days after infection and dropped significantly at day 90 and day 180. Giving a booster dose during 91-180 days after infection induced high level of anti-spike RBD through 180 days. These findings suggest high level but short-lived immunity induced by SARS-CoV-2 infection while sustained immunity required a booster dose administered from 90 days after the infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sritipsukho P, Sinlapamongkolkul P, Satdhabudha A, et al. Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received. Vaccine. 2024. PMID: 38852039. doi:10.1016/j.vaccine.2024.05.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。